Severe Pneumonia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: The inclusion criteria for patients with severe pneumonia are as follows, and patients with non-severe pneumonia are those who meet the diagnostic criteria for pneumonia in the same period, do not meet the diagnostic criteria for severe pneumonia, and sign an informed consent form and agree to collect clinical samples. 1) Meet the criteria for the determination of severe pneumonia formulated by the IDSA/ATS in the United States; 2) The etiological results of severe pneumonia should be clear, and they should contain common and important pathogens, including bacteria such as Streptococcus pneumoniae, Pseudomonas aeruginosa, viruses, influenza virus, new coronavirus, etc., and atypical pathogens should include Legionella pneumophila; 3) The person or the authorized agent understands the purpose of the study, voluntarily participates in the study and signs the informed consent form; 4) Consent to the collection of clinical samples. Specific diagnostic criteria for severe pneumonia are as follows: (1) Meet the diagnostic criteria for pneumonia: 1) Age> 18 years old; 2) Meet the clinical diagnostic criteria: newly developed cough, sputum production, or aggravation of symptoms of pre-existing respiratory diseases, with/without purulent sputum, chest pain, hemoptysis, dyspnea; Fever; signs of pulmonary consolidation and/or crackles; peripheral leukocytes > 10 or Require endotracheal intubation, mechanical ventilation therapy; Sepsis shock requires vasoactive medication after aggressive fluid resuscitation; 2) Secondary Criteria: respiratory rate> 30 breaths/minute; Oxygenation index =7.14mmol/L; Systolic blood pressure 3 minor criteria.
Exclusion criteria
Exclusion criteria: 1) Patients who are participating in other clinical trials; 2) Patients whose etiological type cannot be identified or whose etiological type is a rare pathogen; 3) Pregnant or lactating women who have been clearly diagnosed or have other serious chronic diseases such as cardiac insufficiency, uremia, advanced tumors, severe immunosuppression, etc.; 4) Life expectancy is less than 14 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proteomics features of severe pneumonia in the early stage of hospital admission;Metabolomics features of severe pneumonia in the early stage of hospital admission;Proteomics features and temporal changes in patients with severe pneumonia who died;Metabolomics features and temporal changes in patients with severe pneumonia who died; | — |
Countries
China
Contacts
Beijing Chaoyang Hospital, Capital Medical University